Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Product sales	$ 34,922,000	$ 8,266,000	$ 4,157,000
Product royalty revenues	5,070,000	3,646,000	1,406,000
Research and development reimbursements	799,000	1,134,000	909,000
Contract revenue	21,194,000	2,500,000	41,759,000
Total revenues	61,985,000	15,546,000	48,231,000
Cost of sales	19,496,000	11,258,000	8,101,000
Expenses:
Research and development	13,040,000	18,878,000	20,624,000
Selling, general and administrative	58,869,000	49,345,000	54,685,000
Total expenses	71,909,000	68,223,000	75,309,000
Loss from operations	(29,420,000)	(63,935,000)	(35,179,000)
Interest expense, net	(8,577,000)	(3,267,000)	(2,518,000)
Bargain purchase gain	27,336,000
Other (expense) income, net	(26,000)	64,000	25,000
Loss before income taxes	(10,687,000)	(67,138,000)	(37,672,000)
Income tax benefit	15,972,000	0	0
Net income (loss) attributable to common stockholders	$ 5,285,000	$ (67,138,000)	$ (37,672,000)
Basic:
Weighted average common stock shares outstanding	55,355,802	53,679,134	52,384,876
Basic earnings (loss) per share	$ 0.10	$ (1.25)	$ (0.72)
Diluted:
Diluted weighted average common stock shares outstanding	56,402,479	53,679,134	52,384,876
Diluted earnings (loss) per share	$ 0.09	$ (1.25)	$ (0.72)